News and Trends 2 Jul 2018 Dutch Snake Venom-Derived Clotting Agent Comes Closer to the Clinic Dutch biotech raises €12.5M to complete the preclinical development of its lead compound for acute internal bleeding and bring the drug into clinical trials. VarmX, based in Leiden, the Netherlands, raised a Series A round of €7.5M led by BioGeneration Ventures, with an additional €5M provided by the Netherlands Enterprise Agency as an Innovation Credit. The […] July 2, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Jul 2018 13 Biotech Leaders You Should Know in the UK’s Golden Triangle After listing the top biotech leaders in Munich, we investigated the ‘golden triangle’ in the UK to find out who are the most influential biotech leaders there. The so-called ‘golden triangle’ of universities in Oxford, Cambridge and London concentrates a large percentage of the UK’s biotech research and industry, ranging from big pharma, like AstraZeneca and GSK, […] July 2, 2018 - 8 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2018 Glass Microbiology: From the Microscope to the Art Gallery Artist Luke Jerram is behind Glass Microbiology, a series of beautiful glass-blown microbes that are changing the way we perceive viruses and bacteria. We’ve all seen at some point brightly-colored illustrations of viruses, most likely the feared HIV or an alien-like bacteriophage. These representations feed our imagination and help us understand the tiny but complex world of […] June 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2018 Update: Yet Another ADC Company Makes Bank, This Time in Series B Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […] June 29, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Startup Scout 29 Jun 2018 This French Biotech Links Drugs Together to Target Bone Cancer This week, we’re in Aronnax, France, visiting Atlanthera, a biotech developing more effective treatments for bone cancer using a two-compound approach. Mission: Antlanthera was founded in 2011 with the goal of developing more effective drugs for bone cancer. The company uses biophosphonates, a popular bone-building treatment for osteoporosis, to target bone tissue. Atlanthera’s technology works […] June 29, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2018 Muscular Dystrophy Drug Fails in Phase 2 Trial The stock of Summit Therapeutics has plunged by 80% after announcing that its drug candidate for Duchenne muscular dystrophy failed to meet the primary and secondary endpoints of a Phase II clinical trial. Duchenne muscular dystrophy is a genetic disease that causes progressive muscle deterioration in children born with the disease. The British-American company Summit […] June 28, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 28 Jun 2018 The Race to Get CRISPR to the Clinic: Hope Versus Hype In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into the clinic with a CRISPR therapy. Peter Nell worked at Bayer for many years and was one of the founding team of Casebia Therapeutics. Now […] June 28, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2018 International Fund Raises €300M for Dementia Research The Dementia Discovery Fund has raised $350M (€300M) to support industrial and academic scientists doing early-stage research to develop new dementia medicines. Launched in 2015, the Dementia Discovery Fund (DDF) is dedicated to investing in early-stage ventures that develop disease-modifying therapeutics for all types of dementia, including Alzheimer’s and Parkinson’s. Yesterday, the DDF completed a […] June 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2018 Update: The FDA Approves First Cannabinoid Treatment for Epilepsy Update (26/06/2018): The FDA has approved GW Pharmaceutical’s drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach the market. Published on 20/04/2018 GW Pharmaceuticals has received a unanimous recommendation from the FDA Advisory Committee Meeting supporting the approval of what could soon […] June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 A Biodegradable Plaster Could Help us Treat Mouth Ulcers British researchers and a Danish biotech have joined forces to develop a polymer patch that can treat mouth ulcer patients with long-term steroid release and make the wound-healing process faster. Dermtreat, based in Copenhagen, and researchers from the University of Sheffield’s School of Clinical Dentistry in the UK made a patch from polymers that stick […] June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […] June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic Alzheimer’s drug. The company plans to enroll a total of 90 patients in Spain, France and the UK. Update (14/05/2018): Oryzon has been given approval to expand to France its Phase IIa clinical trial for an epigenetic Alzheimer’s drug. The […] June 25, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email